3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
20
Terminated
4
Withdrawn
3
Unknown
2
Suspended
1
No longer available
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
62
Carcinoma, Non-Small-Cell Lung
43
Triple Negative Breast Neoplasms
24
Ovarian Neoplasms
21
Fallopian Tube Neoplasms
17
Neoplasm Metastasis
15
Lung Neoplasms
15
Endometrial Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
14
Stomach Neoplasms
12
Esophageal Neoplasms
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
9
Neoplasms
8
Esophageal Squamous Cell Carcinoma
8
Colorectal Neoplasms
8
Inflammatory Breast Neoplasms
6
Head and Neck Neoplasms
6
Carcinoma
6
Uterine Cervical Neoplasms
5
Melanoma
5
Carcinoma, Ovarian Epithelial
5
Adenocarcinoma Of Esophagus
5
Peritoneal Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Squamous Cell
4
Urinary Bladder Neoplasms
3
Pancreatic Neoplasms
3
Oropharyngeal Neoplasms
3
Mouth Neoplasms
3
Lung Diseases
3
Interventions
enzalutamide
33
Abiraterone Acetate
29
apalutamide
26
Prednisone
26
Radiotherapy
25
Magnetic Resonance Spectroscopy
25
Androgen Antagonists
24
Leuprolide
22
Radiosurgery
19
darolutamide
18
Docetaxel
17
Gonadotropin-Releasing Hormone
16
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
15
Goserelin
13
gallium 68 PSMA-11
12
bicalutamide
12
Specimen Handling
12
Radiotherapy, Intensity-Modulated
12
abiraterone
11
Radiation
11
pembrolizumab
10
Pluvicto
10
Carboplatin
9
Brachytherapy
9
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
9
relugolix
8
luprolide acetate gel depot
8
Triptorelin Pamoate
8
Standard of Care
8
Nivolumab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Prostatic Neoplasms
×
Paclitaxel
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled